Kineticos’ Operating Executive, Steve Buckanavage, continues his conversation Dr. Jeffrey Skolnik, VP of Clinical Development at Inovio Pharmaceuticals. They start off their discussion by answering the question “If you were starting a clinical program today, what would the requirements be for starting a basket trial that includes hematological, as well as solid tumors?”

Click here to download the full article: Bridges and Barriers to Advancing CAR-T - Part 2


NOTE: Use your cursor to scroll or the tool-bar located at the bottom of this article to review all available pages.


Bridges and Barriers to Advancing CAR-T Therapy - Part 2